Cancer is the Now the Leading Cause of Line-of Duty Death for Firefighters in the U.S.
Unfortunately 50% of the most common cancer types are still diagnosed in the late stages when outcomes are poor and costs are high (1)
That's why StageZero Life Sciences provides advanced diagnostics that can not only identify cancer earlier among first responders, but we can also help identify the early warning signs that can lead to a future cancer diagnosis.
Contact us today to learn moreBecause the Worst Cancer Diagnosis is a Late One |
Our Experience With FirefightersWe have worked with first responders throughout the U.S. and Canada.
ARISTOTLE® is a our proprietary blood test that can detect the molecular signatures of multiple cancers from a single sample of blood to help you find cancer earlier. Our underlying mRNA technology, The Sentinel Principle, has been validated in more than 9,000 patients and used by more than 100,000 patients in North America. (2) Aristotle was selected for publication at the 2020 annual meeting of the American Society of Clinical Oncology (ASCO). |
The Benefits of Finding Cancer Through Early Interventions
|
The average cost of late-stage cancer diagnosis is almost 2-3 times the cost of an early-stage diagnosis (3). Finding cancer earlier reduces costs.
|
Survival rates dramatically improve when cancer is found in the early stages. (1)
|
Our Programs
|
1. Early Cancer Detection
ARISTOTLE is our proprietary mRNA blood test that can detect multiple cancers from a single sample of blood to help find cancer earlier. Aristotle can discretely detect each cancer signature with high sensitivity and specificity. (2) |
2. Early Interventions for Cancer Prevention
Did you know more than 40% of the most common cancers are preventable through modifiable risk factors? (4) AVRT identifies early risk factors that may lead to cancer and provides actionable information to help people adopt lifestyle modifications and pharmaceutical interventions to help reduce their risk. |
References
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
2. Aristotle: A single blood test for pan-cancer screening. Dempsey AA, Chao S, Stamatiou D, Pilcz T, Ying J, Burakoff R. Journal of Clinical Oncology 2020; 38:15_suppl e15037
3. McGarvey, N., Gitlin, M., Fadli, E. et al. Increased healthcare costs by later stage cancer diagnosis. BMC Health Serv Res 22, 1155 (2022). https://doi.org/10.1186/s12913-022-08457-6American
4 GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022 Aug 20;400(10352):563-591. doi: 10.1016/S0140-6736(22)01438-6. PMID: 35988567.
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
2. Aristotle: A single blood test for pan-cancer screening. Dempsey AA, Chao S, Stamatiou D, Pilcz T, Ying J, Burakoff R. Journal of Clinical Oncology 2020; 38:15_suppl e15037
3. McGarvey, N., Gitlin, M., Fadli, E. et al. Increased healthcare costs by later stage cancer diagnosis. BMC Health Serv Res 22, 1155 (2022). https://doi.org/10.1186/s12913-022-08457-6American
4 GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022 Aug 20;400(10352):563-591. doi: 10.1016/S0140-6736(22)01438-6. PMID: 35988567.
